DOCSLIB.ORG

Fatal Hepatitis Associated with Diclofenac

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fatal Hepatitis Associated with Diclofenac Gut: first published as 10.1136/gut.27.11.1390 on 1 November 1986. Downloaded from Gut, 1986, 27, 1390-1393 Case reports Fatal hepatitis associated with diclofenac E G BREEN, J McNICHOLL, E COSGROVE, J MCCABE, AND F M STEVENS From the Department of Medicine, Regional Hospital, Galway, Eire SUMMARY Non-steroidal anti-inflammatory agents (NSAIDS) are a well recognised cause of hepatotoxicity. Diclofenac, a relatively new NSAID, was first introduced into the UK in 1979. Five cases of hepatitis have recently been reported, principally in the French literature. -5 We report the first fulminant case of hepatitis in the English literature in a patient taking diclofenac and indomethacin. Diclofenac is a member of the arylalkanoic group of 100 mg per day for five weeks. Ferrous sulphate one NSAIDS (Fig. 1). Three other agents in this group tablet daily was added on 16 May. The patient was have been shown to be significantly hepatotoxic. admitted to hospital on 26 June. A week before this Ibufenac was withdrawn from circulation because of he had felt unwell with anorexia, nausea, abdominal the frequent rise in transaminases,6 7 the use of discomfort, and dark urine. On admission he was benoxaprofen was stopped in Britain after 10 icteric, the liver edge was palpable 4 cm below the patients died with hepatitis8 9 and more recently a costal margin and there were no signs of chronic fatal case of hepatitis due to pirprofen has been liver disease. Ultrasound showed early ascites with reported."' Early reports about diclofenac showed no obstruction of the biliary tract. A week after that it caused a rise in liver function tests.'' Since admission he developed a maculopapular rash 1983 five reports of hepatitis caused by diclofenac maximal on the trunk, diffuse lymphadenopathy, http://gut.bmj.com/ have been published, including that of a 55 year old and a pyrexia of 39°C. The eosinophil count was French woman, who died with fulminant hepatitis 399x 1)9/l. Laboratory investigations were consist- after a three week course of diclofenac.'-5 ent with fulminant hepatitis and serological markers Indomethacin has been in clinical use for over 20 for viral infection were absent (Table). The patient years and two patients have died from fulminant had no history of foreign travel, blood transfusion, hepatitis caused by indomethacin. 12 '" Other reports alcohol abuse, exposure to toxic chemicals or of hepatotoxicity exist but are infrequent.'4 ' We describe a patient who developed fulminant hepati- on September 28, 2021 by guest. Protected copyright. tis after one month's treatment with indomethacin followed by two months' treatment with diclofenac. CH2COOH Case report A 56 year old farmer started treatment for osteo- arthritis on 9 April, 1985. Before this he had no medical illness and was not taking any medication. He received an intramuscular injection of diclofenac %NH (50 mg) and started indomethacin 75 mg per day for 10 days, and 50 mg per day for the following two weeks. On 2 May he received a further intramus- cular injection of diclofenac (50 mg) and oral diclofenac was substituted for indomethacin. The dose was 75 mg per day for two weeks followed by Address for corrcsponidcncc: I)r E (G 13rccn. Depirtmient of Mclicinie. Rcgional Flospital. (Cilway. Eire. Rcccivcd for publiciation 1f) Mairch 1980. Fig. C(hemicalstrff(trcre of diclofienac. 1390 Gut: first published as 10.1136/gut.27.11.1390 on 1 November 1986. Downloaded from Fatal hepatitis associated with diclofenac 1391 homosexuality. His condition gradually deterio- and hydrocortisone were started. On 13 July aster- rated. The liver reduced in size, the prothrombin ixis and foetor hepaticus were present and the time rose to 37 sec, the serum albumin fell to 23 g/l patient became comatose. On 17 July urine output and gross ascites developed. Lactulose neomvcin fell to 300 ml per day, and the platelet count was 30 000, with no laboratory evidence of disseminated intravascular coagulation. The patient died on 20 Table Laboratory data oni admissioni July, 24 days after admission. Necropsy showed a small liver which weighed 950 g. The histopathology Liver futnc tion telsts Normtial ritoige was of massive hepatic cell necrosis with extensive Albumin 36 g/l (34-48 g/l) centrilobular liver cell dropout (Fig. 2). The portal Prothrombin time 22 secs (14-16 sec) triads showed intense inflammatory infiltrate and Alkaline phosphatasc 321 U/I (30-115 U/1) bridging necrosis was present in the relatively better Bilirubin 115 LImol/l (1-17 LtlloUI) preserved aireas. There was no fibrosis. Bile plug- Alanine aminotransferasc 2110O U/I ((0-4 U/I) Viral screcn ging was present in the renal tubules and the other Hepatitis A- IgM Negativc organs were normal. Hepatitis B - sAg Negative Hepatitis B - IgM - cAntibody Negatis c Discussion Cytomegalovirus Negativc Ebstein-Barr virus Negative Herpes Simplex virus Negatitsc This patient died from fulminant hepatitis, as shown Autoantihodies by the absence of clinical, or histological evidence of Nuclear Negatis c previous liver disease, the occurrence of hepatic Mitochondrial Negativ c Smooth muscle Negatis e encephalopathy three weeks after the onset of White ccll count 5 7xl())/l jaundice, the abnormal prothrombin time and the Ncutrophils 6h5/., massive hepatic cell necrosis. There are three Lymphocytes 2700% possible causes: non-A non-B hepatitis, indometha- Eosinophils 7°/o cin, and diclofenac. The diagnosis of non-A non-B hepatitis is one of exclusion. In this patient all http://gut.bmj.com/ on September 28, 2021 by guest. Protected copyright. Fig. 2 Microscopy of liver showing centriloblular necrosis. Gut: first published as 10.1136/gut.27.11.1390 on 1 November 1986. Downloaded from 1392 Breen, McNicholl, Cosgrove, McCabe, and Stevens screening for viral infection was negative. Two quently accompanies hepatitis caused by benoxa- injections with sterile disposable needles and syr- profen and fenclofenac is now known to cause inges were administered, but transmission of non-A interstitial nephritis. 9 23 This patient, however, non-B hepatitis by this route seems most unlikely. developed oliguria as a terminal event, and necropsy The manifestations of hypersensitivity favour a drug failed to show any specific findings suggestive of a aetiology rather than non-A non-B hepatitis.'" The drug induced nephropathy. predominance of centrilobular necrosis also favours Review of the five published reports of diclofenac a drug aetiology.'7 hepatitis, shows that four patients were women, and Reports of hepatotoxicity with indomethacin are the mean age was 56*8 years (range 45-72). The rare. Two deaths due to fulminant hepatitis have mean duration of treatment was 14 2 weeks (range been published.'2 13 On both occasions treatment 3-24). Two patients had eosinophilia and one was with 100 mg per day for two and a half and patient had a skin rash. On withdrawing the drug, seven months respectively, and treatment was in three patients showed rapid correction of liver progress when the hepatitis occurred. This patient function tests, and the other two patients died from had a smaller dose of indomethacin for a much hepatic failure, one five weeks and the other five shorter period, and treatment had stopped two months, after starting treatment. Three authors months before the onset of hepatitis. There were no suggest toxic metabolic mediated liver damage, and adverse effects or signs of a hypersensitivity reaction one author suggests an immunoallergic mechanism. during treatment with indomethacin. Those that did We consider the latter to be the most likely occur were unlikely to have been caused by a drug mechanism in this patient, in view of the presence of administered two months previously. 17 signs of hypersensitivity, and the exceptional nature Diclofenac is the most likely cause of hepatitis in of the liver damage. The eosinophil count was at the this patient. Hepatitis including fulminant hepatitis upper limit of the normal range, and thus neither due to diclofenac is well established.'-- It usually supports nor excludes this mechanism. occurs after an average of three months' treatment The recent increase in reports of hepatoxicity and may be associated with signs of a hypersensitiv- induced by NSAIDS warrants attention. This is the ity reaction. This patient had taken two months' first report in the English literature of fulminant treatment with diclofenac and hepatitis occurred hepatitis induced by diclofenac. Fortnightly assess- while taking the drug. The signs of a hypersensitivity ment of liver function for the first six months' reaction and the temporal relationship between the treatment with these new agents is advisable. http://gut.bmj.com/ onset of hepatitis and treatment with diclofenac, in Immediately stopping treatment on finding raised the absence of convincing evidence of another liver function tests or at the onset of symptoms such cause, supports diclofenac as being the offending as nausea, anorexia, or abdominal discomfort, is agent. obligatory. Corticosteroid treatment was not suc- The mechanism of arylalkanoic derivative in- cessful in this patient and its role in diclofenac duced hepatitis is not clear. Dunk and Danan favour induced hepatitis has yet to be evaluated. a metabolic rather than a hypersensitivity on September 28, 2021 by guest. Protected copyright. mechanism. I 1) They base this on the absence of hypersensitivity signs in some patients, the initial delay in the onset of hepatitis from the start of References treatment, and the late response to readministration of the drug.' 5 18 Alclofenac, another arylalkanoic I Dunk AA, Walt RP, Jenkins WJ, Sherlock SS. derivative, has been shown to form unstable epox- Diclofenac hepatitis. Br Med J 1982; 284: 1605-6. ides 2 Babany G, Pessayre D, Benhamou JP. Hepatitis which destroy cytochrome P-450.'9 This caused by diclofenac. Gastroenterol C/in Biol 1983; 7: mechanism may be at the basis of other arylalkanoic 316.
Load more

Recommended publications
  • United States Patent (19) 11 Patent Number: 5,955,504 Wechter Et Al
    USOO5955504A United States Patent (19) 11 Patent Number: 5,955,504 Wechter et al. (45) Date of Patent: Sep. 21, 1999 54 COLORECTAL CHEMOPROTECTIVE Marnett, “Aspirin and the Potential Role of Prostaglandins COMPOSITION AND METHOD OF in Colon Cancer, Cancer Research, 1992; 52:5575–89. PREVENTING COLORECTAL CANCER Welberg et al., “Proliferation Rate of Colonic Mucosa in Normal Subjects and Patients with Colonic Neoplasms: A 75 Inventors: William J. Wechter; John D. Refined Immunohistochemical Method.” J. Clin Pathol, McCracken, both of Redlands, Calif. 1990; 43:453-456. Thun et al., “Aspirin Use and Reduced Risk of Fatal Colon 73 Assignee: Loma Linda University Medical Cancer." N Engl J Med 1991; 325:1593-6. Center, Loma Linda, Calif. Peleg, et al., “Aspirin and Nonsteroidal Anti-inflammatory Drug Use and the Risk of Subsequent Colorectal Cancer.” 21 Appl. No.: 08/402,797 Arch Intern Med. 1994, 154:394–399. 22 Filed: Mar 13, 1995 Gridley, et al., “Incidence of Cancer among Patients With Rheumatoid Arthritis J. Natl Cancer Inst 1993 85:307-311. 51) Int. Cl. .......................... A61K 31/19; A61K 31/40; Labayle, et al., “Sulindac Causes Regression Of Rectal A61K 31/42 Polyps. In Familial Adenomatous Polyposis” Gastroenterol 52 U.S. Cl. .......................... 514/568; 514/569; 514/428; ogy 1991 101:635-639. 514/416; 514/375 Rigau, et al., “Effects Of Long-Term Sulindac Therapy On 58 Field of Search ..................................... 514/568, 570, Colonic Polyposis” Annals of Internal Medicine 1991 514/569, 428, 416, 375 11.5:952-954. Giardiello.et al., “Treatment Of Colonic and Rectal 56) References Cited Adenomas With Sulindac In Familial Adenomatous Poly U.S.
    [Show full text]
  • Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation, Final, July 2009
    Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) July 2009 Drug Safety Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave., Bldg. 51, rm. 2201 Silver Spring, MD 20993-0002 Tel: 301-796-3400; Fax: 301-847-8714; E-mail: [email protected] http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or Office of Communication, Outreach, and Development, HFM-40 Center for Biologics Evaluation and Research Food and Drug Administration 1401 Rockville Pike, Rockville, MD 20852-1448 Tel: 800-835-4709 or 301-827-1800 http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) July 2009 Drug Safety TABLE OF CONTENTS I. INTRODUCTION............................................................................................................. 1 II. BACKGROUND: DILI ................................................................................................... 2 III. SIGNALS OF DILI AND HY’S
    [Show full text]
  • Benoxaprofen Irony Is Inescapable That While Manuscripts
    BRITISH MEDICAL JOURNAL VOLUME 285 18 SEPTEMBER 1982 809 Br Med J (Clin Res Ed): first published as 10.1136/bmj.285.6344.809-a on 18 September 1982. Downloaded from favourable groups of alcoholics (such as single, trials and post-marketing surveillance pro- the carefully controlled and monitored clinical divorced, or widowed men and women) is as grammes, often undergo extensive revision trial. Unless there is prompt reporting of the yet unknown but may appear doubtful to the before acceptance for publication, paid results of such trials by the sponsoring drug practising clinician.3 The statement that, advertisements extolling only the virtues of company to all governmental agencies in "Treatment may actually make some alco- various products generally are accepted countries marketing or planning to market a holics worse" by protecting them from the without modification. particular drug, the Committee on Safety of consequences of their drinking or by fostering In the face of the need to maintain fiscal Medicines, the Food and Drug Administration, inactivity surely applies only to utterly inade- viability while upholding the highest editorial and similar agencies in other countries will quate "treatment." The risks arising from the standards, what is a medical journal to do in not be acting on the best available information. behaviour of well-meaning "enablers" who regard to advertising? The issue needs to be shelter the alcoholic from experiencing the explored by both editors and medical associa- SIDNEY M WOLFE painful effects of his drinking on himself (and tions at their meetings. One proposal has been EVE BARGMANN others) and the importance of fostering the raised' and seconded2 for a "physician Health Research Group, patient's responsibility for his recovery, his boycott" of drugs that are unethically pro- Washington DC 20036 own initiative, and active participation in the moted.
    [Show full text]
  • Cross-Reactive Mechanism for the False Elevation of Free Triiodothyronine in the Patients Treated with Diclofenac
    Endocrine Journal 2001, 48 (6), 717-722 NOTE Cross-Reactive Mechanism for the False Elevation of Free Triiodothyronine in the Patients Treated with Diclofenac KEIZO KASONO, HAJIME HIKINO*, SHINJI FUJINO**, NoBUYUKI TAKEMOTO*, TosHIHIRO KAI*, KIYosHI YAMAGUCHI***, FUMio KONISHI* AND MASANOBU KAWAKAMI Department of Endocrinology and Metabolism, Jichi Medical School, Omiya Medical Center, 1-847, Amanuma-cho, Saitama 330-8503, Japan *Department of Surgery , Jichi Medical School, Omiya Medical Center, 1-847, Amanuma-cho, Saitama 330-8503, Japan **Department of Pathology , Jichi Medical School, Omiya Medical Center, 1-847, Amanuma-cho, Saitama 330-8503, Japan ***Department of Neurology , Jichi Medical School, Omiya Medical Center, 1-847, Amanuma-cho, Saitama 330-8503, Japan Abstract. We report three cases of patients exhibiting a false elevation of serum free triiodothyronine (FT3) as a result of a cross-reaction with diclofenac. The first case is a 66-yr-old woman with a long history of rheumatoid arthritis (RA). The patient was receiving diclofenac for the treatment of her RA. The patient was subsequently diagnosed as having thyroid papillary adenocarcinoma and received a subtotal thyroidectomy. After the operation, the patient exhibited postoperative hypothyroidism except for a gradual elevation of FT3. The other two patients also exhibited an elevated serum FT3 level after the administration of diclofenac. Serum FT3 levels in these pa- tients decreased to normal or below normal after diclofenac administration was discontinued. In the first case, the elimination of immunoglobulin from the sera using polyethylene glycol precipitation did not reduce the FT3 level. In our hospital, Vitros ECi (enhanced chemiluminescence enzyme immunoassay) system and Vitros FT3 kit were used for FT3 assay.
    [Show full text]
  • Benoxaprofen
    BRITISH LONDON, SATURDAY 14 AUGUST 1982 Br Med J (Clin Res Ed): first published as 10.1136/bmj.285.6340.459 on 14 August 1982. Downloaded from MEDICAL^s JOURNAL Benoxaprofen Two years after benoxaprofen (Opren) was launched in a The mode of action of benoxaprofen appears to differ blaze of publicity the Committee on Safety of Medicines has from that of other non-steroidal anti-inflammatory agents. It suspended its product licence on the grounds of concern acts directly on mononuclear cells, inhibiting their chemotactic about serious side effects (see p 519). The public has been response; it inhibits the lipoxygenase enzyme; and it has a alarmed by the total of 61 deaths in patients, mostly elderly, mild inhibitory action on the formation of other prosta- taking benoxaprofen and by the admission of the Committee glandins.'8 19 This combination of properties is of great on Safety of Medicines that it has received 3500 reports of theoretical interest, since nearly all other non-steroidal adverse reactions. Has the Committee on Safety of Medicines anti-inflammatory drugs appear to act by inhibiting prosta- acted too slowly on this occasion ? What are the- lessons to be glandin synthetase. There is some preliminary evidence that learnt ? benoxaprofen may have disease-modifying properties in Firstly, the benoxaprofen affair shows the dangers of current rheumatoid arthritis.20 marketing policies by some pharmaceutical companies. After A drug with unusual properties may be expected to have its clinical trials the drug was put on to the market with massive unusual side effects-and both the frequency and nature of publicity on radio and in newspapers encouraging patients to these effects have been surprising.
    [Show full text]
  • An in Vitro Approach to Detect Metabolite Toxicity Due to CYP3A4
    Toxicology 216 (2005) 154–167 An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics Luisella Vignati ∗, Elisa Turlizzi 1, Sonia Monaci, Pietro Grossi, Ruben de Kanter, Mario Monshouwer 2 Department of Pre-Clinical Development, Nerviano Medical Sciences S.r.l., V.le Pasteur, 10, 20014, Nerviano, MI, Italy Received 22 June 2005; received in revised form 3 August 2005; accepted 3 August 2005 Available online 19 September 2005 Abstract Many adverse drug reactions are caused by the cytochrome P450 (CYP) dependent activation of drugs into reactive metabolites. In order to reduce attrition due to metabolism-mediated toxicity and to improve safety of drug candidates, we developed two in vitro cell-based assays by combining an activating system (human CYP3A4) with target cells (HepG2 cells): in the first method we incubated microsomes containing cDNA-expressed CYP3A4 together with HepG2 cells; in the second approach HepG2 cells were transiently transfected with CYP3A4. In both assay systems, CYP3A4 catalyzed metabolism was found to be comparable to the high levels reported in hepatocytes. Both assay systems were used to study ten CYP3A4 substrates known for their potential to form metabolites that exhibit higher toxicity than the parent compounds. Several endpoints of toxicity were evaluated, and the measurement of MTT reduction and intracellular ATP levels were selected to assess cell viability. Results demonstrated that both assay systems are capable to metabolize the test compounds leading to increased toxicity, compared to their respective control systems. The co-incubation with the CYP3A4 inhibitor ketoconazole confirmed that the formation of reactive metabolites was CYP3A4 dependent.
    [Show full text]
  • Reviewer Guidance
    Reviewer Guidance Conducting a Clinical Safety Review of a New Product Application and Preparing a Report on the Review U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2005 Good Review Practices Reviewer Guidance Conducting a Clinical Safety Review of a New Product Application and Preparing a Report on the Review Additional copies are available from: Office of Training and Communication Division of Drug Information, HFD-240 Center for Drug Evaluation and Research Food and Drug Administration 5600 Fishers Lane Rockville, MD 20857 (Tel) 301-827-4573 http://www.fda.gov/cder/guidance/index.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2005 Good Review Practices TABLE OF CONTENTS I. INTRODUCTION............................................................................................................. 1 II. GENERAL GUIDANCE ON THE CLINICAL SAFETY REVIEW .......................... 2 A. Introduction....................................................................................................................................2 B. Explanation of Terms ....................................................................................................................3 C. Overview of the Safety Review .....................................................................................................4 D. Differences in Approach to Safety and Effectiveness Data ........................................................4
    [Show full text]
  • And Thin-Layer Chromatography (Drug Skreen)1)
    Oeilerich, Külpmann and Haeckel: Drug screening by enzyme immunoassay and .tliin-layer chromatography 275 J. Clin. Chem. Clin. Biochem. Vol. 15, 1977, pp. 275-283 Drug Screening by Enzyme Immunoassay (EMIT) and Thin-Layer Chromatography (Drug Skreen)1) By M. Oellerich, W. R. Külpmann and/?. Haeckel Technical Assistance : F. Behrends,L hberner and K. Petry Institut für Klinische Chemie (Geschäftsführcnder Direktor: Prof. Dr. Dr. J. Büttner) Medizinische Hochschule Hannover (Received June 12/December 16, 1976) Herrn Prof. Dr. Dr. h. c. G. Schettler zum 60. Geburtstag gewidmet Summary: Urine samples (n = 300) were examined for drugs by thin-layer chromatography ("Drug Skreen", Brink- mann Corp.) and by the "Enzyme Multiplied Immunoassay Technique" ("Emit", Syva Corp.). The results of both methods were compared for the detection of opiates, barbiturates and amphetamines. In more than 90% of the determinations identical results were obtained with both methods. About 10% of the results of the Emit barbiturate assay differed from those of thin-layer chromatography and therefore had to be further investigated by gas liquid chromatography. It could be demonstrated that the barbiturate determination by the Emit system correlated better with the results of gas liquid chromatography. From the results of this study it is suggested that thin-layer chromato- graphy is used as a screening test, and to confirm positive results with other methods such as Emit. If the abuse of barbiturates or opiates is suspected the corresponding Emit test should also be performed, even in cases of a negative thin-layer Chromatograph*, -screening. Confirmation with a third method such as gas liquid chromatography is necessary, if thin-layer chromatography and Emit lead to divergent results.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Søgeprotokol for Nationale Kliniske Retningslinjer
    Søgeprotokol for nationale kliniske retningslinjer Projekttitel/aspekt NKR behandling af patienter med lumbal spinalstenose – Søgning efter primærlitteratur Fagkonsulent /projektleder Rikke Rousing / Maria Herlev Ahrenfeldt Søgespecialist Kirsten Birkefoss Senest opdateret 23.12.2016 Fokuserede spørgsmål Bør patienter med lumbal spinalstenose have tilbudt aktiv PICO 1: behandling i form af superviseret træning fremfor vanlig behandling? PICO 2: Bør patienter med lumbal spinalstenose have tilbudt ledmobiliserende behandling frem for vanlig behandling? PICO 3: Bør patienter med lumbal spinalstenose have tilbudt paracetamol frem for ingen smertestillende behandling? PICO 4: Bør patienter med lumbal spinalstenose have tilbudt non steroid antiinflammatorisk medicin (NSAID) frem for ingen smertestillende behandling? PICO 5: Bør patienter med lumbal spinalstenose have tilbudt smertestillende medicin i form af opioider i tillæg til eventuel behandling med svage smertestillende? PICO 6: Bør patienter med lumbal spinalstenose have tilbudt muskelrelaxantia i tillæg til eventuel behandling med svage smertestillende? PICO 7: Bør patienter med lumbaspinalstenose have tilbudt medicin for neuropatiske smerter? PICO 8: Bør patienter med lumbal spinalstenose have tilbudt kirurgisk dekompression i tilfælde af manglende effekt af ikke kirurgisk behandling? PICO 9: Bør patienter med lumbal spinalstenose have tilbudt stivgørende operation med eller uden instrumentering i tillæg til dekompression? PICO 10: Bør patienter opereret for lumbal spinalstenose tilbydes
    [Show full text]
  • Variable in Their Efficacy? a Description of Ion Trapping
    Annals of the Rheumatic Diseases 1993; 52: 241-243 241 HYPOTHESIS Why are non-steroidal anti-inflammatory drugs so variable in their efficacy? A description of ion trapping G A Ellis, D R Blake Hypothesis Non-steroidal anti-inflammatory drugs vary in Our hypothesis is that acidic non-steroidal their aqueous solubility, but most are highly anti-inflammatory drugs (NSAIDs) undergo albumin bound and will be co-distributed with ion trapping in acidotic tissue and that this this protein. Diffusion of an NSAID into the affects not only their gastrotoxicity, which is cell follows Fick's law, as it is dependent on the well known, but also their selectivity for, and concentration gradient across the plasma their efficacy in, inflammatory joint disease. membrane and the lipid/water partition Tissue acidosis may not be a feature of all coefficient of the drug molecule. chronic inflammatory disease states, but it does For weak acids, such as most NSAIDs, the occur in inflammatory joint disease and is effective concentration gradient is that of the highly variable depending on the extent of the non-ionised form, as ionised molecules are not mismatch between synovial perfusion and lipid soluble metabolic demand. This mismatch is influ- HD D- + H+ enced not only by disease activity, but also by Non-ionised Ionised joint movement, which causes transient hypoxic episodes. Interventions, such as rest The position ofthe equilibrium depends on the and drug treatment, would serve to reduce ion intrinsic ionisation constant of the molecule trapping and, therefore, NSAID efficacy (pKa) and on the pH value of the aqueous through their effects on disease activity.
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs B.L
    Br. J. clin. Pharmac. (1983), 16, 633-638 A METHOD FOR PREDICTING THE PHOTOTOXICITY OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS B.L. DIFFEY1 & S. BROWN2 Departments of Medical Physics' and Pharmacy2, Dryburn Hospital, Durham, DH1 5TW 1 The photosensitisation potential of several non-steroidal anti-inflammatory drugs (NSAIDs) has been investigated in vivo using an irradiation monochromator. 2 Evidence ofabnormal, immediate photosensitivity was obtained in 13 of the 38 patients taking one of four out of seven different NSAIDs. 3 A simple mathematical model was developed to predict the likelihood of photosensitivity occurring with a given drug by considering the mass of drug normally ingested, the spectral absorption characteristics of the drug, and the quantity and spectral quality of the radiation (e.g. sunlight) to which the patient may be exposed. Keywords phototoxicity non-steroidal anti-inflammatory drugs Introduction The non-steroidal anti-inflammatory drugs (NSAIDs) differences in skin pigmentation reflecting variations have gained prominence in recent years as useful in the penetration of light into the skin. therapeutic agents in the management of rheumatoid The NSAIDs, although chemically distinct, share and osteoarthritis. However several of these drugs many common properties. The exact mode of action have been reported as inducing adverse cutaneous of each drug is not fully understood, but all these photosensitive reactions (Committee on Safety of drugs are potent inhibitors of the enzyme prosta- Medicines, personal communication). The photo- glandin synthetase (Simon & Mills, 1980). This sensitisation potential of many of these drugs, parti- property undoubtedly plays an important part in the cularly benoxaprofen, has subsequently been con- anti-inflammatory effect, but there is no clearly de- firmed by laboratory investigation (Wiskemann, 1981; fined relationship between the inhibitory potency of a Kligman & Kaidbey, 1982; Ferguson et al., 1982; drug against prostaglandin synthetase in vitro and Diffey & Daymond, 1983; Diffey etal., 1983).
    [Show full text]